Cargando…

Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma

BACKGROUND: The phase 3 LIBERTY ASTHMA QUEST study (ClinicalTrials.gov: NCT02414854) in patients with uncontrolled, moderate-to-severe asthma has demonstrated the efficacy and safety of dupilumab 200 and 300 mg every 2 weeks versus placebo. This post hoc analysis assessed the effect of dupilumab on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Corren, Jonathan, Katelaris, Constance H., Castro, Mario, Maspero, Jorge F., Ford, Linda B., Halpin, David M.G., Rice, Megan S., Radwan, Amr, Deniz, Yamo, Rowe, Paul J., Teper, Ariel, Djandji, Michel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2021
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551561/ https://www.ncbi.nlm.nih.gov/pubmed/34266940 http://dx.doi.org/10.1183/13993003.04498-2020

Ejemplares similares

Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma
por: Corren, Jonathan, et al.
Publicado: (2023)

Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization
por: Corren, Jonathan, et al.
Publicado: (2023)

Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma
por: Castro, Mario, et al.
Publicado: (2020)

Dupilumab efficacy in adolescents with uncontrolled, moderate‐to‐severe asthma: LIBERTY ASTHMA QUEST
por: Maspero, Jorge F., et al.
Publicado: (2021)

Dupilumab is effective in type 2‐high asthma patients receiving high‐dose inhaled corticosteroids at baseline
por: Bourdin, Arnaud, et al.
Publicado: (2020)

Improvement in Lung Function with Dupilumab Does Not Predict Its Effects on Reducing Asthma Exacerbation
por: Hanania, Nicola A, et al.
Publicado: (2022)

Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate‐to‐severe type 2 asthma
por: Papi, Alberto, et al.
Publicado: (2022)

Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function
por: Pavord, Ian D, et al.
Publicado: (2020)

Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma
por: Busse, William W., et al.
Publicado: (2018)

Long-term efficacy of dupilumab in severe asthma by baseline oral corticosteroid dose
por: Domingo, Christian, et al.
Publicado: (2023)

Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils
por: Bleecker, Eugene R., et al.
Publicado: (2023)

Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µL(−1)
por: Rabe, Klaus F., et al.
Publicado: (2022)

Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation
por: Busse, William W., et al.
Publicado: (2021)

Dupilumab Improves Outcomes in Patients with Chronic Rhinosinusitis with Nasal Polyps and Coexisting Asthma Irrespective of Baseline Asthma Characteristics
por: Busse, William Walter, et al.
Publicado: (2023)

Effect of Dupilumab in Korean Patients With Uncontrolled Moderate-to-Severe Asthma: A LIBERTY ASTHMA QUEST Sub-analysis
por: Rhee, Chin Kook, et al.
Publicado: (2022)

Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: Association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS‐24 and SINUS‐52 trials
por: Bachert, Claus, et al.
Publicado: (2022)

Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study
por: Fiocchi, Alessandro G., et al.
Publicado: (2023)

Long-term effect of dupilumab on prevention of lung function decline in patients with uncontrolled moderate-to-severe asthma: ATLAS trial design
por: De Prado Gomez, Lucia, et al.
Publicado: (2023)

Repeated exacerbation of asthma: An intrinsic phenotype of uncontrolled asthma
por: Jain, Neeraj, et al.
Publicado: (2019)

Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps
por: Hopkins, Claire, et al.
Publicado: (2021)

Improvement in Health-Related Quality of Life with Dupilumab in Patients with Moderate-to-Severe Asthma with Comorbid Chronic Rhinosinusitis with/without Nasal Polyps: An Analysis of the QUEST Study
por: Hopkins, Claire, et al.
Publicado: (2022)

The Effect of Dupilumab on Intractable Chronic Rhinosinusitis with Nasal Polyps in Japan
por: Fujieda, Shigeharu, et al.
Publicado: (2020)

Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study
por: Corren, Jonathan, et al.
Publicado: (2021)

Efficacy and safety of dupilumab for the treatment of uncontrolled asthma: a meta-analysis of randomized clinical trials
por: Xiong, Xiao-feng, et al.
Publicado: (2019)

Real-life effectiveness of montelukast administered as monotherapy or in combination with inhaled corticosteroid (ICS) in pediatric patients with uncontrolled asthma
por: Bérubé, Denis, et al.
Publicado: (2014)

Effectiveness of montelukast administered as monotherapy or in combination with inhaled corticosteroid in pediatric patients with uncontrolled asthma: a prospective cohort study
por: Bérubé, Denis, et al.
Publicado: (2014)

Reduced exacerbation frequency and prednisone dose in patients with ABPA and asthma treated with dupilumab
por: van der Veer, Tjeerd, et al.
Publicado: (2021)

Rapid and Continuing Improvements in Nasal Symptoms with Dupilumab in Patients with Severe CRSwNP
por: Bachert, Claus, et al.
Publicado: (2022)

Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps
por: Hellings, Peter W., et al.
Publicado: (2022)

Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
por: Bansal, Ashish, et al.
Publicado: (2021)

Type 2 Low Biomarker Stability and Exacerbations in Severe Uncontrolled Asthma
por: Viinanen, Arja, et al.
Publicado: (2023)

Improvement in patient‐reported “taste” and association with smell in dupilumab‐treated patients with severe chronic rhinosinusitis with nasal polyps from the SINUS‐24 and SINUS‐52 trials
por: Peters, Anju T., et al.
Publicado: (2022)

Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS‐52 is unaffected by eosinophilic status
por: Fujieda, Shigeharu, et al.
Publicado: (2021)

The Role of Dupilumab in Severe Asthma
por: Ricciardolo, Fabio Luigi Massimo, et al.
Publicado: (2021)

Conjunctivitis in dupilumab clinical trials
por: Akinlade, B., et al.
Publicado: (2019)

Dupilumab in the management of moderate-to-severe asthma: the data so far
por: Barranco, Pilar, et al.
Publicado: (2017)

Dupilumab in the Treatment of Moderate to Severe Asthma: An Evidence-Based Review
por: Rathinam, Kiran Kumar, et al.
Publicado: (2019)

Exacerbation of Eosinophilic Granulomatosis With Polyangiitis After Administering Dupilumab for Severe Asthma and Eosinophilic Rhinosinusitis With Nasal Polyposis
por: Tanaka, Shunya, et al.
Publicado: (2022)

Dupilumab‐associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian setting
por: Foley, Peter, et al.
Publicado: (2022)

AROMA: real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps
por: Siddiqui, Shahid, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k06ji3athqqm1g56mn76hsq9ta